

1

2

3

4 **The efficacy of Tripterygium Glycosides in the treatment of Chinese patients**
5 **with thyroid-associated orbitopathy: A systematic review and meta-analysis**

6

7

8 Mingzhe Li ^a, Bingchen Wei ^{b*}, Tianshu Gao ^c, Chenghan Gao ^c

9

10

11

12 1 Internal Medicine Department, the Third Affiliated Hospital of Liaoning University of Traditional Chinese
13 Medicine, Shenyang, China

14 2 The First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, China

15 3 The First Affiliated Hospital, Liaoning University of Traditional Chinese Medicine, Shenyang, China

16

17 *Correspondence: Bingchen Wei,

18 E-mail: m18540119119@163.com

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

20 Abstract

21 **Objective:** This study aims to conduct a systematic review of the effectiveness and safety of Tripterygium
22 Glycosides interventions in the treatment of Chinese patients with thyroid-associated orbitopathy (TAO).

23 **Methods:** A literature search was conducted using PubMed for English sources, and the CNKI, Chinese
24 Biomedical Database, Wanfang Database, and VIP Database for Chinese sources. The search period extended
25 from the beginning of the databases' creation to Dec. 2023. The keywords used in the search were
26 hyperthyroidism, thyroid-related immune orbitopathy (TRIO), ophthalmopathy, and Tripterygium Glycosides.
27 Various combinations of search terms were used, depending on the database being queried. All the trials included
28 in the study were clinical randomized controlled trials (RCTs).

29 **Results:** 33 RCTs or quasi-RCTs that met the inclusion criteria were included. The meta-analysis included 27
30 RCTs. 6 RCTs were excluded from the analysis due to the absence of a control group, but they were still included
31 in the systematic review. 27 RCTs or quasi-RCTs involving 2,134 patients were included in the meta-analysis.
32 The TRIO patients in the treatment group received Tripterygium Glycosides in combination with Thiamazole,
33 Prednisone, Levothyroxine sodium, or a combination of these medications. While the TRIO patients in the control
34 group were treated with Thiamazole, Prednisone, Levothyroxine sodium, or a combination of these treatments, the
35 meta-analysis results show that the overall effectiveness rate of the treatment group and the control group was $P =$
36 0.05 , $I^2 = 0.33 < 0.5$ [MD = 4.45, 95% CI (3.31, 5.99), $P < 0.00001$]. The former was significantly superior to the
37 latter. At the same time, a risk assessment was conducted for the study of the 2 groups. The former was
38 significantly superior to the latter. Furthermore, the clinical effectiveness rate of eyeball prominence was $P < 0.$
39 00001 , $I^2 = 0.98 > 0.5$ [MD = 2.40, 95% CI (2.28, 2.51), $P < 0.00001$]. The clinical effectiveness rate of CAS
40 score was $P < 0.00001$, $I^2 = 0.89 > 0.5$ [MD = 1.68, 95% CI (1.50, 1.85), $P < 0.00001$]. The clinical effectiveness
41 rate of FT₃ was $P < 0.00001$, $I^2 = 0.98 > 0.5$ [MD = 0.95, 95% CI (0.81, 1.08), $P < 0.00001$], the clinical
42 effectiveness rate of FT₄ was $P < 0.00001$, $I^2 = 0.95 > 0.5$ [MD = 2.12, 95% CI (1.99, 2.25), $P < 0.00001$], and
43 the clinical effectiveness rate of TSH was $P < 0.00001$, $I^2 = 0.89 > 0.5$ [MD = -0.19, 95% CI (-0.21, -0.17), $P < 0.$
44 00001].

45 **Conclusion:** The experience with the treatment of TAO using Tripterygium Glycosides was promising. The
46 existing evidence suggests that treatment with Tripterygium Glycosides may be more effective in enhancing the
47 response rate, quality of life, and FT₃ levels compared to treatment with Prednisone, Levothyroxine sodium,
48 and/or Thiamazole alone.

49 **Keywords:** Hyperthyroidism; Thyrotoxicosis; Thyroid-associated orbitopathy; Tripterygium Glycosides; Meta-analysis

50 **1. Introduction**

51 Thyroid-associated ophthalmopathy (TAO) is a group of autoimmune diseases involving orbital and periocular
52 tissues associated with genetic, environmental, and immunologic factors, with the highest incidence of orbital disease.
53 The pathogenesis of the disease is complex, with the majority of patients suffering from Graves' disease (GD), which
54 has a prevalence of up to 40%. Moreover, in 80% of patients experiencing both hyperthyroidism and ophthalmopathy,
55 the clinical symptoms progress rapidly within 2 years of disease onset, forming a vicious cycle [1]. Graves'
56 ophthalmopathy is also known as thyroid eye disease (TED), thyroid-associated orbitopathy (TAO), and Graves'
57 orbitopathy (GO) [2,3]. Tripterygium wilfordii is the Chinese herbal anti-inflammatory immunomodulator, which is the
58 first studied and used in China, known as the "Chinese herbal hormone". It has the functions of promoting blood
59 circulation and collateralization, dispelling wind and dehumidification, detumescence and pain, detoxification, anti-
60 inflammatory and etc. Extract of tripterygium wilfordii is often used in the treatment of autoimmune diseases. There is a
61 large number of clinical studies having found that tripterygium wilfordii can be used in the treatment of thyroid-
62 associated ophthalmopathy [4]. Currently, the use of Tripterygium and its extracts for treating hyperthyroidism
63 exophthalmos is gaining clinical attention. Comprehensive analysis and evaluation of RCTs on TAO with Tripterygium
64 Glycosides were carried out in this paper according to principles of evidence-based medicine. A meta-analysis was
65 conducted to provide objective and accurate evidence, and to assess the effectiveness of Tripterygium Glycosides in
66 treating hyperthyroidism exophthalmos. The aim was to offer guidance and a foundation for the clinical use of this
67 medication.

68 Tripterygium wilfordii is a perennial vine species in the Celastraceae family, extensively utilized in traditional
69 Chinese medicine for the treatment of autoimmune and inflammatory diseases. According to the *Compendium of*
70 *Materia Medica*, Tripterygium wilfordii is documented as a treatment for conditions such as swelling, edema,
71 accumulation, yellow and white pox, long-term incurable malaria, constipation, leprosy, and falls.

72 The protocol of this network meta-analysis was registered in PROSPERO with ID CRD42021247873. We present
73 the following article in accordance with the PRISMA reporting checklist (available at [https://dx.doi.org/10.21037/apm-](https://dx.doi.org/10.21037/apm-21-1307)
74 21-1307).

75 **2. Methods**

76 **2.1. Literature sources and search**

77 The publications utilized in the meta-analysis were identified through searches of the China National Knowledge

78 Infrastructure (CNKI), PubMed, Web of Science, Wanfang Database, VIP Database, and EMBASE. The search period
79 extended from the inception of the databases' construction to December 2023, and the search was conducted in Chinese
80 or English. The key words used in the search were “Hyperthyroidism”, “Thyroid related immune orbitopathy” or
81 “TRIO”, “Ophthalmopathy” or “Tripterygium Glycosides”, “Tripterygium, Tripterygium wilfordii”, “Tripterygium
82 wilfordii Hook f.”, “Tripterygium wilfordii multiglycoside”. Different combinations of search terms were used,
83 depending on the selected database. The selected publications were clinical trials published in medical journals. 2
84 reviewers independently evaluated English and Chinese literature for inclusion. Any disagreements were resolved
85 through discussion.

86 **2.1.1. Literature selection**

87 Research on the types of RCTs (RCT or Controlled Clinical Trial, CCT) for the treatment of TAO, regardless of
88 whether blinded or not.

89 Diagnose standard according to the *Diagnosis of clinical diseases based on the improvement of the standard* [5]: (1)
90 typical ocular symptoms; (2) with hyperthyroidism or a history of hyperthyroidism; and (3) excluding other similar
91 diseases.

92 Exclusion criteria: (1) myopia; (2) orbital inflammatory pseudotumor; (3) carotid-cavernous sinus fistula or dural
93 artery cavernous sinus; (4) extraocular muscle lymphatic tumor; (5) primary orbital tumor; (6) ocular metastasis; and (7)
94 intracranial tumors and other diseases.

95 TAO classification according to Wilmar's simple classification standard. Grade I (mild): eyeball prominence <
96 18mm, with upper eyelid retraction, gaze, eyelid, and conjunctival edema; Grade II (moderate): eyeball prominence is
97 18-20 mm, with ocular involvement; Grade III (severe): eyeball prominence > 20 mm, with corneal involvement and
98 vision disorders [6].

99 **2.1.2. Literature extraction**

100 Studies were excluded if they were: (1) animal experiments; (2) clinical trials from which no relevant data could be
101 extracted; (3) repeatedly published studies; (4) studies involving patients with serious mental disorders or dementia; (5)
102 studies involving patients with serious systemic symptoms that may significantly affect their ability to perform daily
103 living activities, including syncope or coma, seizure-like headache, and cachexia; and (6) studies involving pregnant or
104 breastfeeding women.

105 All trials included in the analysis were extracted by two reviewers. Once completed, any disagreements regarding
106 data extraction and study evaluation were resolved through discussion with the third reviewer. All the trials included in
107 the analysis contain information on study design, patient characteristics, and medication use.

108 **2.2. Clinical efficacy**

109 Clinical efficacy judgement [7,8]: Cure is defined as the disappearance of eye symptoms, obvious retraction of the
110 eye, protrusion of the eyeballs < 18 mm, or a reduction in protrusion by > 3 mm. The treatment was significantly
111 effective as the eye symptoms disappeared, but the reduction in exophthalmos > 2 mm. The degree of reduction in
112 exophthalmos is effective, ranging from 1-2 mm. Invalid: The degree of exophthalmos showed no obvious change, or
113 exophthalmos reduced by < 1 mm.

114 **2.3. Quality assessment**

115 Following the quality assessment standard recommended by the Cochrane Review Handbook 5.0 [9]. The bias risk
116 assessment tool involved six aspects: (1) random distribution method; (2) concealment of allocation decisions; (3)
117 blinding of research subjects, operators of the therapeutic plan, or those measuring the results; (4) result integrity; (5)
118 selective presentation of study findings; and (6) other potential sources of bias.

119 Each research result was evaluated based on the six aspects mentioned above and categorized as "YES" (low-
120 degree bias), "NO" (high-degree bias), or "unclear" (lacking relevant information or uncertain bias condition). Two
121 evaluators cross-verified the quality assessment results of the inclusive trials, and any differences in opinions were
122 resolved through discussion or third-party arbitration.

123 **2.4. Statistical analysis**

124 Meta-analysis was performed using the Rev Man software (Version 5.3) from The Cochrane Collaboration website.
125 First, we performed clinical heterogeneity and methodological heterogeneity analyses for all the trials included.
126 Statistical heterogeneity was evaluated by the Chi-squared (χ^2) test and heterogeneity were considered present if $P \leq$
127 0.10. A quantitative assessment of heterogeneity was performed using I^2 where $I^2 > 50\%$ indicated high heterogeneity
128 among study results. Study results were pooled for analysis using a fixed effects model when there was no statistical
129 heterogeneity or using a random effects model when statistical heterogeneity was detected. For dichotomous variables,
130 odds ratio (OR) and 95% confidence interval (CI) was determined. For hypothesis testing, the U test was used and the
131 results were presented as Z and P values. The differences in the efficacy between interventions were considered
132 statistically significant if $P \leq 0.05$. The results of hypothesis testing are presented in a forest plot.

133 **3. Results**

134 **3.1. Identified studies and characteristics**

135 The literature search yielded a total of 211 published studies. The abstracts of these studies were reviewed, and
 136 subsequently, 142 studies were excluded due to a lack of controls. The 69 potentially relevant RCTs were further
 137 reviewed, of which 36 were excluded due to the low Jaded score. Finally, 33 RCTs or quasi-RCTs that met the
 138 inclusion criteria were included. 27 RCTs were included in the meta-analysis, while 6 RCTs were excluded due to the
 139 absence of a control group, but they were included in the systematic review (Fig 1). A total of 33 RCTs with a diagnosis
 140 of TAO were included (Table 1).

141 **Fig 1 Flow diagram for identification of eligible literatures for this meta-analysis.**

142 **Table 1 The main characteristics of the trials.**

First author	Gender (Male/Female)	Range of age and average age (years)	Tme (weeks)	Intervention		Main outcomes
				Treatment group	Control group	
Nie M[10]	92 (51/41)	31-56 (43.81±5.12)	36	Thiamazole, Prednisone, Glycosides tablets	Thiamazole, Prednisone	Eyeball prominence, TSH, FT ₄ , Clinical effect
Tian ML[11]	44 (17/27)	20-62 (40.98±10.45)	24	⁹⁹ Tc-MDP, Glycosides tablets	Glycosides tablets	Eyeball prominence, FT ₃ , FT ₄ , Clinical effect
Chang XY[12]	86 (51/35)	29-58 (44.37±10.67)	12	Thiamazole, Prednisone, Glycosides tablets	Thiamazole, Prednisone	Clinical effect
Xue F[13]	100 (-/-)	- (-)	12	Thiamazole, Levothyroxine Sodium, Prednisone, Glycosides tablets	Thiamazole, Levothyroxine Sodium, Prednisone	Eyeball prominence, Clinical effect
Gao X[14]	90 (55/35)	30-50 (40.91±10.11)	Blank	Thiamazole, Prednisone, Glycosides tablets	Thiamazole, Prednisone	Clinical effect, Quality of life score
Chi PW[15]	108 (55/53)	21-49 (33.9±5.3)	12	Thiamazole, Prednisone, Glycosides tablets	Thiamazole, Prednisone	Eyeball prominence, Clinical effect
Li XL[16]	80 (35/45)	20-46 (32.2±3.5)	12	Levothyroxine Sodium, Thiamazole, Prednisone, Glycosides tablets	Levothyroxine Sodium, Thiamazole, Prednisone	Eyeball prominence, Clinical effect
Yue X[17]	53 (20/33)	- (40.2±14.1)	Blank	Glycosides tablets, Levothyroxine Sodium, Methylprednisolone, Hydrochlorothiazide, Potassium chloride sustained-release tablets	Blank	Clinical effect, CAS score
Ma CF[18]	80 (34/46)	20-49 (33.2±1.2)	12	Thiamazole, Glycosides tablets	Thiamazole	Eyeball prominence, Clinical effect
Ao W[19]	80 (31/49)	21-45 33.2±2.4	12	Levothyroxine Sodium, Thiamazole, Prednisone, Glycosides tablets	Levothyroxine Sodium, Thiamazole, Prednisone	Eyeball prominence, Clinical effect
Li XH[20]	114 (41/73)	20-55 (35.70±8.20)	12	Levothyroxine Sodium, Thiamazole, Prednisone, Glycosides tablets	Levothyroxine Sodium, Thiamazole, Prednisone	Eyeball prominence, Clinical effect
Luo J[21]	50 (16/43)	- (46.23±12.17)	16	Methylprednisolone, Prednisone, Glycosides tablets	Methylprednisolone, Prednisone	Clinical effect, CAS Score
Xv JP[22]	64 (29/55)	- (33.0±11.5)	12	Levothyroxine Sodium, Thiamazole, Prednisone, VitD, Glycosides tablets	Levothyroxine Sodium, Thiamazole, Prednisone, VitD	Eyeball prominence, Clinical effect, Peripheral blood cytokine levels
Zhang JF[23]	49 (19/30)	22-47 (28.3±6.9)	12	Thiamazole, Prednisone, Levothyroxine sodium, Glycosides tablets	Thiamazole, Prednisone, Levothyroxine sodium	Eyeball prominence, Clinical effect
Jiang WH[24]	84 (21/63)	- (38.45±1.75)	12	Thiamazole, Prednisone, Glycosides tablets	Thiamazole, Prednisone	Clinical effect, CAS Score
Cui HH[25]	75 (-/-)	12-70 (40.9±13.1 & 37.9±14.5)	12	Prednisone, Glycosides tablets	Prednisone	Clinical effect, CAS score
Liao XD[26]	66 (27/39)	18-50 (32.6±2.9)	12	Thiamazole, Prednisone, Glycosides tablets	Thiamazole, Prednisone	Clinical effect
Lin YL[27]	122 (41/81)	18-66 (39.25)	12	Thiamazole, Prednisone, Levothyroxine sodium, Glycosides tablets	Blank	Clinical effect
Wu JT[28]	60 (22/38)	19-58 (-)	12	Thiamazole, Prednisone, Levothyroxine sodium, Glycosides tablets	Blank	Clinical effect
Gou XY[29]	48 (12/36)	16-70 (43.20±10.15)	12	Cetirizine tablets, Glycosides tablets	Prednisone	Clinical effect, CAS score
Zhang ZY[2]	98 (38/60)	19-49 (33.50)	12	Thiamazole, Prednisone, Levothyroxine sodium, Glycosides tablets	Thiamazole, Prednisone, Levothyroxine sodium	Clinical effect
He XH[30]	39 (13/26)	16-65 (47.24±11.16)	16	Glycosides tablets, Prednisone, ATD	Prednisone, ATD	Clinical effect, Eyeball prominence, T-cells
Zheng ST[31]	40 (9/31)	19-48 (35±5.5)	12	ATD, Nimesulide, Glycosides tablets, ⁹⁹ Tc-MDP	ATD	Clinical effect, FT ₃ , FT ₄ , TSH, TGAb, TPO-Ab
Wei XB[32]	84 (35/49)	20-56 (35.4)	12	Thiamazole, Prednisone, Levothyroxine sodium, Glycosides tablets	Thiamazole, Prednisone, Levothyroxine sodium	Eyeball prominence, Clinical effect
Wang XS[33]	106 (44/62)	- (38.80)	16	Glycosides tablets, ⁹⁹ Tc-MDP	Prednisone	Eyeball prominence, CAS Score, Clinical effect
Mu YD[34]	61 (23/38)	17-64 (37.48)	12	Thiamazole, Prednisone, Glycosides tablets	Blank	Clinical effect
Xie DH[35]	60 (17/43)	17-49 (36.00±5.50)	12	ATD, ⁹⁹ Tc-MDP, Thiamazole	ATD	Clinical effect, FT ₃ , FT ₄ , TSH, TGAb, TPO-Ab
Zuo LJ[36]	215 (89/126)	- (48.07)	12	ATD, ⁹⁹ Tc-MDP, Thiamazole, Glycosides tablets	ATD	Clinical effect, FT ₃ , FT ₄ , TSH, TGAb, TPO-Ab
Wang L[37]	49 (19/30)	20-53 (-)	12	Thiamazole, Glycosides tablets	Thiamazole	CAS Score

Wang W[38]	48 (21/27)	30-63 (44)	16	¹³¹ I, Glycosides tablets	¹³¹ I, Prednisone	Clinical effect, CAS Score
Lv JZ[39]	22 (9/13)	20-52 (31)	12	Thiamazole, Prednisone, sodium, Glycosides tablets	Levothyroxine Blank	FT ₃ , FT ₄ , TSH, TGAb, TPO-Ab
Luo Y[40]	86 (56/30)	17-52 (34±1.52)	8	Glycosides tablets	VitB ₁₂ , VitC	Eyeball prominence
Wang XM[41]	36 (14/22)	15-60 (-)	8-52	Glycosides tablets	Blank	FT ₃ , FT ₄ , TGAb, CIC

143 Notes: FT₃: free triiodothyronine; FT₄: free thyroxine; TGAb: thyroglobulin antibody; CIC: cycle immune complex;

144 TSH: thyroid stimulating hormone; ATD: Antithyroid Drug; CAS Score: clinical activity score.

145 3.2. Quality assessment

146 According to the quality evaluation standard for all included RCTs and CCTs for quality assessment and analysis.

147 11 RCT articles were rated as B grade. 16 articles received a C grade. The evaluation and results are presented in Table

148 1 and 2. Trials of poor quality (D grade) were excluded.

Table 2. The methodological quality of the trials.

First author	Year	City, Province, Country	Random	Blind method	Baseline consistency	Fall off	Follow up	Adverse eventss	Grade
Nie M[10]	2021	Changyuan, Henan, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	B
Tian ML[11]	2020	Puyang, Henan, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	C
Chang XY[12]	2019	Tieling, Liaoning, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	C
Xue F[13]	2019	Weifang, Shandong, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	C
Gao X[14]	2018	Lingyuan, Liaoning, China	Unclear	Unclear	Consensus	Unclear	Unclear	Unclear	C
Chi PW[15]	2017	Xuchang, Henan, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Mentioned	B
Li XL[16]	2017	Yulin, Shaanxi, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	C
Yue X[17]	2017	Zhengzhou, Henan, China	Unclear	None	Consensus	Unclear	Unclear	Mentioned	B
Ma CF[18]	2016	Bayannur, Inner Mongolia, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	C
Ao W[19]	2015	Zhengzhou, Henan, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	C
Li XH[20]	2015	Anyang, Henan, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	C
Luo J[21]	2015	Enshi, Hubei, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Mentioned	B
Xv JP[22]	2014	Jinhua, Zhejiang, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Mentioned	B
Zhang JF[23]	2014	Shaoxing, Zhejiang, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	B
Jiang WH[24]	2013	Huangshi, Hubei, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	C
Cui HH[25]	2013	Nanjing, Jiangsu, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Mentioned	B
Liao XD[26]	2012	Leshan, Sichuan, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	B
Lin YL[27]	2012	Nanning, Guangxi, China	Unclear	None	Consensus	Unclear	Unclear	Unclear	C
Wu JT[28]	2012	Jiyuan, Henan, China	Unclear	None	Consensus	Unclear	Unclear	Mentioned	B
Gou XY[29]	2012	Chongqing, China	Mentioned	Unclear	Consensus	Unclear	Unclear	None	B
Zhang ZY[2]	2010	Pingdingshan, Henan, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	B
He XH[30]	2010	Guiyang, Guizhou, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Mentioned	B
Zheng ST[31]	2010	Siping, Jilin, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	C
Wei XB[32]	2009	Luoyang, Henan, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Unclear	B
Wang XS[33]	2009	Hengshui, Hebei, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Mentioned	C
Mu YD[34]	2009	Shangqiu, Henan, China	Unclear	None	Consensus	Unclear	Unclear	Unclear	C
Xie DH[35]	2007	Zhuhai, Guangdong, China	Mentioned	Unclear	Consensus	Unclear	Unclear	Mentioned	B
Zuo LJ[36]	2007	Kunming, Yunnan, China	Mentioned	Unclear	Consensus	Unclear	Unclear	None	C
Wang L[37]	2007	Yurao, Zhejiang, China	Unclear	Unclear	Consensus	1 case	Unclear	Mentioned	B
Wang W[38]	2004	Xinxiang, Henan, China	Mentioned	Unclear	Consensus	Unclear	Mentioned	Unclear	B
Lv JZ[39]	2003	Ningbo, Zhejiang, China	Unclear	None	Consensus	Unclear	Unclear	Mentioned	B
Luo Y[40]	2002	Taiyuan, Shanxi, China	Unclear	None	Consensus	Unclear	Unclear	Unclear	C
Wang XM[41]	1995	Yangzhou, Jiangsu, China	Unclear	None	Consensus	Unclear	Unclear	Unclear	C

151 3.3. Results of meta-analysis

152 33 RCTs or CCTs were published between 2002 and 2021 in China. There were 2,134 cases in 27 RCTs, with
153 1,104 cases in the treatment group and 1,030 cases in the control group. The treatment group received Tripterygium
154 Glycosides in combination with Thiamazole, Prednisone, Levothyroxine sodium, or a combination of these medications.
155 While the TRIO patients in the control group were treated with Thiamazole, Prednisone, Levothyroxine sodium, or a
156 combination of these treatments. The treatment effect was categorized into four grades: cured, significantly effective,
157 effective, and invalid.

158 Heterogeneity among studies was assessed using Cochran's Q test. The P value ($P < 0.01$, $I^2 < 0.5$) of the Q test $<$
159 0.01 , a random effect model was used; otherwise, a fixed effect model was used. For each model, the effect summary
160 odds ratio (OR) and its 95% CI were calculated.

161 Meta-analysis results showed that the overall effectiveness rate of TAO treatment in the treatment group and the
162 control group was $P = 0.05$, $I^2 = 0.33 < 0.5$ [MD = 4.45, 95% CI (3.31, 5.99), $P < 0.00001$], with the former
163 significantly outperforming the latter. At the same time, a risk assessment was conducted for both groups in the study
164 (Fig 2).

165 Fig 2 The clinical effectiveness rate.

166 The clinical effectiveness rate of eyeball prominence was $P < 0.00001$, $I^2 = 0.98 > 0.5$ [MD = 2.40, 95% CI (2.28,
167 2.51), $P < 0.00001$] (Fig 3).

168 Fig 3 The clinical effectiveness of the eyeball prominence.

169 The clinical effectiveness rate of CAS score was $P < 0.00001$, $I^2 = 0.89 > 0.5$ [MD = 1.68, 95% CI (1.50, 1.85), P
170 < 0.00001] (Fig 4).

171 Fig 4 The clinical effectiveness of the eye CAS score.

172 The clinical effectiveness rate of FT₃ was $P < 0.00001$, $I^2 = 0.98 > 0.5$ [MD = 0.95, 95% CI (0.81, 1.08), $P < 0.$
173 00001] (Fig 5A), the clinical effectiveness rate of FT₄ was $P < 0.00001$, $I^2 = 0.95 > 0.5$ [MD = 2.12, 95% CI (1.99,
174 2.25), $P < 0.00001$] (Fig 5B), and the clinical effectiveness rate of TSH was $P < 0.00001$, $I^2 = 0.89 > 0.5$ [MD = -0.19,
175 95% CI (-0.21, -0.17), $P < 0.00001$] (Fig 5C).

176 Fig 5 The clinical effectiveness rate of the FT₃, FT₄, and TSH.

177 3.4. Adverse events

178 11 studies reported adverse events. In Chi PW's study [15], 7 instances of nausea and vomiting, 3 instances of
179 reduced appetite, and 2 instances of diarrhea were reported in the control group. In the observation group, 2 cases of
180 nausea and vomiting, 1 case of reduced appetite, and 1 case of diarrhea were reported. In Yue X's study [17], adverse

181 reactions mainly occur during hormone shock and the application of somatostatin. Among them, there were 21 cases of
182 abdominal distension, 5 cases of diarrhea, 11 cases of nausea, 5 cases of vomiting, and 3 cases of hypoglycemia, mainly
183 during the use of somatostatin. Additionally, there were 13 cases of abnormal blood glucose: 10 cases of elevated
184 fasting blood glucose levels and 3 cases of early morning hypoglycemia. The elevated fasting blood glucose mainly
185 occurred during the hormone shock treatment period. After 1 week, the fasting blood glucose levels were within the
186 normal range upon re-examination. Exciting insomnia mainly occurs during the hormone pulse therapy period, and the
187 symptoms disappear after the completion of the pulse therapy. There were 4 cases of transient elevated blood pressure,
188 4 cases of abnormal liver function, and 1 case of hypokalemia. In Luo J's study [21], 8 cases in the observation group
189 experienced weight gain, elevated blood sugar, elevated blood pressure, and upper abdominal discomfort, respectively.
190 In the control group, 15 cases experienced weight gain, hirsutism, epigastric discomfort, elevated blood glucose,
191 elevated blood pressure, and elevated liver transaminase. In Xv JP's study [22], the control group had 3 cases of weight
192 gain, 1 case of osteoporosis, and 3 cases of peptic ulcers. In the treatment group, there were 3 cases of mild increases in
193 serum alanine aminotransferase and 3 cases of decreased menstrual flow. In Cui HH's study [25], 2 cases experienced
194 mild menstrual abnormalities, 2 cases experienced stomach discomfort, 1 case had mild transaminase abnormalities, 1
195 case gained weight during medication, and exhibited Cushing's face in the control group. After 1 month of medication,
196 limb muscle stiffness occurred, but no significant changes in blood glucose were observed in all patients. There were 4
197 cases of mild menstrual abnormalities and 1 case of erythra in treatment group II. In Wu JT's study [28], 4 cases
198 showed a decrease in WBC, 2 cases experienced gastrointestinal reactions, and 1 case had mild liver dysfunction. All of
199 them recovered after receiving symptomatic treatment. In He XH's study [30], 3 cases experienced weight gain and
200 hirsutism, while 2 cases experienced acid reflux and upper abdominal discomfort in the treatment group. In Wang XS's
201 study [33], there were 4 cases of short-term blood glucose elevation and 7 cases of insomnia due to excitement in the
202 control group during the treatment process. The aforementioned side effects gradually disappeared with the decrease in
203 hormone dosage, and no special treatment is needed. In Xie DH's study [35], a small number of patients experienced
204 vascular pain at the ⁹⁹Tc MDP infusion site. The discomfort symptoms disappeared after the infusion speed was reduced
205 in the treatment group. Some patients experienced weight gain and excessive nighttime urination after receiving low
206 doses of dexamethasone, and no abnormalities were found in routine blood and urine tests. After the treatment, and
207 routine blood and urine tests did not reveal any abnormalities. In Wang L's study [37], 1 woman experienced
208 amenorrhea and withdrew from the observation. However, she recovered after discontinuing the medication. In Lv JZ's
209 study [39], 21 cases experienced anorexia, nausea, vomiting, and diarrhea, and their symptoms were relieved.

210 **3.5. Risk of bias within studies**

211 Publication bias analysis was conducted on these 27 pieces of literature using a funnel plot, which resulted in a

212 symmetric distribution. Begg's test and Egger's test were also conducted. Both of the P values were > 0.05 , indicating
213 that there was no publication bias in the included trials. All the matching points were found within the 95% CI.

214 The bias was evaluated by conducting a funnel plot analysis of the Tripterygium Glycosides treatment for TAO.
215 The accuracy improved as the sample size increased. The amount of literature included is insufficient, scattered within
216 the pyramid, and symmetrically distributed alongside the axis, indicating minimal bias (Fig 6A). The points
217 corresponding to the CAS score (Fig 6C), FT₄ (Fig 6E), and TSH (Fig 6F) in the included trials are primarily situated
218 within the 95% CI, with a scattered distribution within the range, basically symmetrical on both sides, and presenting a
219 funnel-shaped shape, indicating a small publication bias in the trials included. The eyeball prominence (Fig 6B)
220 corresponding points were outside the range of the 95% CI. This may be attributed to factors such as small sample
221 studies, non-significant results not being published or cited. The corresponding point of FT₃ (Fig 6D) is asymmetric on
222 both sides of the axis.

223 **Fig 6 Funnel plot of the literatures analyzed in the meta-analysis.**

224 4. Discussion

225 TAO is a multifactorial ocular disorder caused by thyroid disease, which often manifests as eye redness, eye pain,
226 exophthalmos, edema, and impaired movement of periocular muscles, etc. 40%-70% of TAO patients suffer from
227 hyperthyroidism. Currently, TAO is clinically categorized into two types: one is ocular infiltrative type, also known as
228 endocrine ophthalmoplegia or malignant Graves' ophthalmopathy, which accounts for 5%-10% of patients with
229 hyperthyroidism. The other is the non-infiltrative type of ophthalmoplegia, also known as simple or benign
230 exophthalmoplegia, which is usually caused by sympathetic stimulation of the periorbital or upper facial muscles.
231 Ocular infiltrative TAO is an autoimmune disease caused by hyperplasia, lymphocytic infiltration and edema of the
232 retro-ocular tissues and is influenced by a variety of factors, such as smoking, genetics and the environment [18,44].

233 The early pathologic changes in these diseases are the infiltration of lymphocytes and serum cells into the
234 periocular muscles and connective tissues [45-47].

235 During the course of the disease, there is a buildup of collagen in the periocular muscles, which leads to fibroblasts
236 and fat cell deposits, the presence of which is of greater significance because it indirectly confirms that the disease
237 undergoes a longer and slower progression. The presence of fat deposits is more significant because it indirectly
238 confirms that the disease undergoes a longer and slower progression. Current research suggests that the correlation
239 between thyroid disease and ocular symptoms may explain the following findings: (1) edema leading to an increase in
240 the volume of the contents of the eye sockets; (2) the production of hydrophilic glucosamines and peptidoglycans; and
241 (3) an accumulation of adipose tissue in the eye sockets.

242 At the present time, the combined use of tretinoin preparations for the treatment of infiltrative TAO is widely used

243 in the clinic. This study found that treatment with Tripterygium Glycosides may be more effective in enhancing the
244 response rate, quality of life, and FT₃ levels compared to treatment with Prednisone, Levothyroxine sodium, and/or
245 Thiamazole alone. Although adverse reactions were still present in the control group, overall the rate of adverse events
246 was lower in the observation group and the clinical benefit was much higher than in the control group. At the same time,
247 a large body of medical evidence shows that Tripterygium Glycosides is effective in the treatment of eye protrusion in
248 hyperthyroidism. It can inhibit cellular and humoral immunity and improve the immune status of the body. It has also
249 been shown to inhibit the formation of self-antigens in the tissues behind the eye, thereby reducing eye protrusion [48].

250 Tripterygium Glycosides is a traditional herbal medicine that originated from China. It has been widely used in
251 China for the treatment of various diseases, including rheumatic diseases, skin diseases, and diabetic nephropathy. In
252 recent years, there have been international studies conducted on Tripterygium Glycosides by renowned institutions such
253 as Harvard University and the University of California, Los Angeles (U.S.A.), the Institute of Pharmacology and Osaka
254 University (Japan), the Siberian Branch of the Russian Academy of Sciences and the Russian Federal Institute of
255 Medical and Biotechnological Research (Russia), as well as the Indian Academy of Medical Sciences and the
256 University of Delhi (India). The research conducted in these countries has mainly focused on studying the
257 pharmacological effects, clinical applications, quality control, and other aspects of Tripterygium Glycosides.

258 Through systematic analysis, we found that the clinical results of applying Tripterygium Glycosides were
259 significantly better than those of the control group. This fully explains the safety, reliability, and precise clinical
260 efficacy of the use of Tripterygium Glycosides in the treatment of hyperthyroid eye protrusion. In addition,
261 Tripterygium Glycosides may improve the efficacy of the basic treatment and may lead to a reduction of the drug dose
262 or complete discontinuation of the treatment. Based on these characteristics, Tripterygium Glycosides treatment may be
263 an ideal solution for hyperthyroidism-like herniated eye disease.

264 It is important to note that long-term use of Tripterygium Glycosides can cause some damage to various body
265 systems. For example, long-term use of Tripterygium Glycosides at higher-than-average doses can lead to reversible
266 liver and kidney damage, while approximately 20% of patients experience gastrointestinal reactions such as loss of
267 appetite, nausea, vomiting, abdominal pain, diarrhea, or constipation. As for the hematopoietic system, the effects of
268 Tripterygium Glycosides use are mainly manifested in the form of a decrease in the number of white blood cells and
269 platelets included [49,50]. It has even been found that long-term use of Tripterygium Glycosides causes skin and
270 mucosal reactions such as oral mucosal ulcers, dryness of the mouth and eyes, roughness and dryness of the skin, rashes,
271 skin sclerosis, and increased melanin production, which is usually associated with the inhibition of the IL-23/IL-17
272 pathway [51,52]. In addition, long-term use of Tripterygium Glycosides can inhibit ovarian function and cause
273 menstrual disorders such as decreased menstrual flow or amenorrhea in women, and in men, it may lead to a decrease in

274 sperm count or sperm motility [53,54].

275 Despite the inevitable problems associated with the use of Tripterygium Glycosides in the treatment of disease, its
276 benefits in the treatment of various diseases cannot be ignored. Currently, there are several meta-analyses of interest due
277 to the efficacy of Tripterygium Glycosides in the treatment of renal diseases, dermatological disorders, rheumatoid
278 arthritis, and nephrotic syndrome⁵⁵⁻⁵⁸. Therefore, it is crucial to conduct a multicenter randomized, double-blind clinical
279 trial to study the efficacy of trehalose in TAO [59,60].

280 **5. Conclusion**

281 This meta-analysis demonstrates that the experience with the treatment of TAO using Tripterygium Glycosides
282 was promising. The existing evidence suggests that treatment with Tripterygium Glycosides may be more effective in
283 enhancing the response rate, quality of life, and FT₃ levels compared to treatment with Prednisone, Levothyroxine
284 sodium, and/or Thiamazole alone.

285 **Declaration of Competing Interest**

286 The authors declare that the research was conducted in the absence of any commercial or financial relationships
287 that could be construed as a potential conflict of interest. We declare that this manuscript is original, has not been
288 published before and is not currently being considered for publication elsewhere. The manuscript has been read and
289 approved by all the mentioned authors.

290 **References**

- 291 1.Ying JM. Progress of Chinese medicine in treating hyperthyroid exophthalmos. *Journal of Traditional Chinese*
292 *Medicine*.25:979-981(2009).
- 293 2.Zhang ZY, Wang JH. Tripterygium Glycosides with tapazole and prednisone in the treatment of hyperthyroidism
294 exophthalmos. *Journal of Medical Forum*. 31 (8): 110-111(2010).
- 295 3.Webb MS, John stone S, Morris TJ, Kennedy A, Gallagher R, Harasym N, et al. In vitro and in vivo characterization
296 of a combination chemotherapy formulation consisting of vinorelbine and phosphatidyl bine. *European Journal of*
297 *Pharmaceutics and Bio pharmaceutics*. 65 (165): 289-299(2010).
- 298 4.Li XW. Clinical observation of 50 cases of children with purpura nephritis treated with Tripterygium Glycosides
299 tablets. *Jiangsu Medical Journal*. 12: 664-665(1987).
- 300 5.Ministry of health of the people's Liberation Army General Logistics Department. Diagnosis of clinical diseases
301 based on the improvement of the standard. *Beijing: People's military medical press*. 1198-1991(1987).

- 302 6.Ministry of Health, PRC. Guiding principle of clinical research on new drugs of Traditional Chinese Medicine.
303 *Beijing: The Medicine Science and Technology Press of China.* section 1: 168(1993).
- 304 7.Wiersinga WM, Prummel MF. Grave's ophthalmopathy: a rational approach to treatment. *Trends Endocrinol*
305 *Metabolism.* 13 (7): 280(2002).
- 306 8.Gu MJ, Wu WY, Liu CH, Liu XL, Li X, Liu ZM. Efficacy of prednisone in the treatment of thyroid associated
307 ophthalmopathy on adrenocortical function. *Journal of Xi'an Jiaotong University: Medical Sciences.* 24 (2): 177-
308 178(2003).
- 309 9.Higgins JPT, Green S.Cochrane Handbook for Systematic Reviews of Interventions Version 5.3 [updated March,
310 2015].*The Cochrane Collaboration*,(2015).
- 311 10.Nie M. Efficacy evaluation of Tripterygium wilfordii polyglycoside combined with Thiamazole and prednisone
312 acetate tablets in the treatment of hyperthyroid exophthalmos. *Heilongjiang Journal of Traditional Chinese*
313 *Medicine.* 50(3):162-163(2021).
- 314 11Tian ML. Therapeutic effect of Tripterygium wilfordii polyglycoside combined with technetium 99-
315 methylenediphosphonate on thyroid associated ophthalmopathy. *Practical Clinical Journal of Integrated*
316 *Traditional Chinese and Western Medicine.* 20(5):17-18(2020).
- 317 12.Chang XY. Effect of Tripterygium wilfordii polyglycoside combined with tapazole and prednisone on
318 hyperthyroidism exophthalmos. *Guide of China Medicine,* 17(21):167-168.
319 DOI:10.15912/j.cnki.gocm.(2019).21.129(2019).
- 320 13.Xue F, Zhang WJ. Analysis of the symptom and outcome of hyperthyroidism exophthalmos treated with
321 Tripterygium wilfordii glycosides. *World Latest Medicine Information.* 19(46):214. DOI:10.19613/j.cnki.1671-
322 3141.2019.46.127(2019).
- 323 14.Gao X. Evaluation of the clinical efficacy of Tripterygium wilfordii polyglycoside, tapazole and prednisone in the
324 treatment of hyperthyroid exophthalmos. *Guide of China Medicine.* 16(2):187-188.
325 DOI:10.15912/j.cnki.gocm.2018.02.157(2018).
- 326 15.Chi PW. Clinical analysis of Tripterygium wilfordii polyglycoside combined with Thiamazole and prednisone in the
327 treatment of hyperthyroid exophthalmos. *Journal of North Pharmacy.* 14(9):34-35(2017).
- 328 16.Li XL, Ma T. Clinical effect of tripterygium glycosides combined with tazobactam and prednisone on patients with
329 hyperthyroid exophthalmos. *Clinical Research and Practice.* 2(22):75-76. DOI:10.19347/j.cnki.2096-
330 1413.201722037(2017).

- 331 17.Yue X, Wang YY, Yang Y, Wen SM, Sun LG. Clinical efficacy and safety analysis of glucocorticoids combined
332 with somatostatin and Tripterygium wilfordii glycosides in the treatment of thyroid associated ophthalmopathy.
333 *Henan Medical Research*. 26(1): 31-33(2017).
- 334 18.Ma CF, Wang YS. Clinical efficacy of Tripterygium wilfordii glycosides combined with Methimazole in the
335 treatment of hyperthyroid exophthalmos. *World Latest Medicine Information*. 16(75):104(2016).
- 336 19.Ao W. Observation on the therapeutic effect of combination therapy of Tabazole, prednisone, and Tripterygium
337 wilfordii glycosides in patients with hyperthyroidism exophthalmos. *Medical Journal of Chinese People's Health*.
338 27(13):95-96(2015).
- 339 20.Li XH. Clinical analysis of Tripterygium wilfordii glycosides combined with Tabazolindolone in the treatment of
340 hyperthyroidism exophthalmos. *Clinical Research*. 23(5): 60-61(2015).
- 341 21.Luo J, Huang J, Ye M. The observation of curative effect of glucocorticoids combined with Glucosida Tripterygii
342 TOTA in the treatment of Graves' ophthalmopathy. *Practical Journal of Clinical Medicine*. 12(5): 174-176(2015).
- 343 22.Xv JP, Xv C, Chen J, Jin ZH, Zheng HF, Zhu J. Graves The level of cytokines in peripheral blood of
344 ophthalmopathy and the effect of Tripterygium wilfordii polyglycoside intervention. *China Journal of Chinese*
345 *Materia Medica*. 39(3): 544-547(2014).
- 346 23.Zhang JF, Kong YZ, Pan HZ. Clinical efficacy of the treatment of hyperthyroidism exophthalmos with Tripterygium
347 Glycosides tablets. *Chinese Rural Health Service Administration*. 6: 761-762(2014).
- 348 24.Jiang WH. Clinical observation of Tripterygium wilfordii polyglycoside combined with tapazole and prednisone in
349 the treatment of hyperthyroidism exophthalmos. *World Health Digest*. 10(22): 178-179(2013).
- 350 25.Cui HH, Ye XZ, Li YL, Lu B, Peng L, Xv YX, et al. Clinical efficacy of mycophenolate mofetil and other
351 immunosuppressive drug in the treatment of thyroid associated ophthalmopathy. *Chinese Journal of Clinicians*
352 *(Electronic Edition)*. 7(24):11197-11200(2013).
- 353 26.Liao XD. Clinical observation of hyperthyroidism exophthalmos treated with Tripterygium Glycosides combined
354 with methimazole and prednisone. *China Health Care and Nutrition*. 10: 1514-1515(2012).
- 355 27.Lin YL. Treatment 122 cases of hyperthyroidism exophthalmos treated with Tripterygium Glycosides tablets
356 combined with methimazole and prednisone. *China Journal of Pharmaceutical Economics*. 7 (5): 119-120(2012).
- 357 28.Wu JT. Clinical analysis of hyperthyroidism exophthalmos treated with Tripterygium Glycosides tablets combined
358 with methimazole and prednisone. *Contemporary Medicine*. 18 (22): 79-80(2012).
- 359 29.Gou XY, Cheng G. Clinical Study on Certirizine Combined Tripterygium Glycosides for Treating 24 Cases of
360 Thyroid Associated Ophthalmopathy. *China Pharmaceuticals*. 21(18):85-86(2012).

- 361 30.He XH, Kong DM. Tripterygium wilfordii polyglycosides combined with low-dose prednisone in the treatment of 23
362 cases of Graves' ophthalmopathy. *New Chinese Medicine*. 42(8): 65-66(2010).
- 363 31.Zheng ST, Zhang B, Mei F. Multiple enhanced immunosuppression for hyperthyroid exophthalmos: Yunke,
364 Nimesulide, Tripterygium wilfordii polyglycoside tablets for Graver ophthalmopathy. *World Health Digest*. 7(23):
365 65-66(2010).
- 366 32.Wei XB. The effect of Tripterygium Glycosides tablets on the treatment of hyperthyroidism exophthalmos. *China*
367 *Modern Doctor*. 20: 97+101(2009).
- 368 33.Wang XS, Li GL, Wang Q, Ge CJ, Zhang L. Clinical study of Yunke combined with Tripterygium wilfordii
369 glycosides in the treatment of thyroid associated ophthalmopathy. *Chinese Journal of Practical Ophthalmology*.
370 27(12):1369-1371(2009).
- 371 34.Mu YD. Case analysis of Tripterygium wilfordii united tapazole prednisone in the treatment of 61 cases of
372 thyrotoxic exophthalmoses. *China Medical Herald*. 6 (23): 25-27(2009).
- 373 35.Xie DH, Sun L, Shu XC, Ye LH, Shen J, Lu HY. Combination of technetium [⁹⁹Tc] methylenediphosphonate,
374 dexamason and tripterygium glucosides in treatment of Graves ophthalmopathy. *Chinese Journal of New Drugs*
375 *and Clinical Remedies*. 26(12): 905-908(2007).
- 376 36.Zuo LJ, Yang JS. Observation on the therapeutic effect of ¹³¹I combined with Tripterygium wilfordii glycosides on
377 Graves' ophthalmopathy. *China Health Care*. 15(19): 51-52(2007).
- 378 37.Wang L. Immunosuppressive drug therapy for Graves ophthalmopathy. *Zhejiang Clinical Medicine Journal*.
379 9:197(2007).
- 380 38.Wang W, Yang B, Sun HJ, Zhou YL. Clinical study of ¹³¹I and glucoside tripterygium total tablets on
381 Graves' ophthalmopathy. *Chinese Journal of Nuclear Medicine*. 24(03): 38-39(2004).
- 382 39.Lv JZ. Prednisone and Tripterygium Glycosides tablets in the treatment of hyperthyroidism exophthalmos. *Zhejiang*
383 *Journal of Integrated Traditional Chinese and Western Medicine*. 13 (5): 299-230(2003).
- 384 40.Luo Y, Zheng DW, Wang X, He YQ, Li DP. Clinical Observation of Tripterygium wilfordii Polysaccharide Tablets
385 in the Treatment of Thyroid related Orbital Lesions. *China Journal of Chinese Ophthalmology*. 12(2):95-97(2002).
- 386 41.Wang XM.Clinical study on the treatment of hyperthyroidism exophthalmos with Glycosides tablets. *Journal of*
387 *Jiangsu TCM*. 16 (10): 41-42(1995).
- 388 42.Shen ZY. The summary and analysis of the influence of Traditional Chinese Medicine on immune function. *Chinese*
389 *Journal of Integrated Traditional and Western Medicine*. 12:443-6(1992).
- 390 43.Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, Natural History, Risk Factors, and Prevention
391 of Graves' Orbitopathy. *Front Endocrinol (Lausanne)*.11:615993. doi: 10.3389/fendo.2020.615993(2020).

- 392 44. Bai Y. Thyroid disease-basic and clinical. *Beijing: Science and Technology Literature Press*. 466-476(2002).
- 393 45. Shi FX. Observation on the effect of treating Graves eye disease with Tripterygium Glycosides tablets. *New Chinese*
394 *Medicine*. 21:472-473(1990).
- 395 46. Yang JH, Duan JG. The progress of hyperthyroidism exophthalmos with the treatment of Chinese medicine
396 treatment. *New Journal of Traditional Chinese Medicine*. 35:74(2003).
- 397 47. Li GM, Li GM, Chen LD. A comparative observation on hyperthyroidism exophthalmos with clinical combination
398 of Traditional Chinese and Western Medicine. *Chinese Journal of Information on Traditional Chinese Medicine*.
399 15:62(2008).
- 400 48. Zheng JR, Lv Y. Clinical and experimental studies of Tripterygium. *Journal of Traditional Chinese Medicine*.
401 23:74-78(1982).
- 402 49. Liu F. Pharmacological research and clinical application of Tripterygium Glycosides tablets. *Chinese Traditional*
403 *Patent Medicine*. 24:385(2002).
- 404 50. Li LX, Jin RM, Li Yikui, Fu SG, Huang J, Zhu ZL, et al. Study on the immunosuppressive effect and safety range of
405 multiple dosing of Tripterygium Glycosides tablets. *Chinese Journal of New Drugs and Clinical Remedies*.
406 25:248(2006).
- 407 51. Chu WL, Kang ZF, Chan SL, Li WY, Liu J. Research progress on inhibition of ocular neovascularization by Chinese
408 herbal monomers. *Journal of Traditional Chinese Ophthalmology*. 29:166-169(2019).
- 409 52. Qin TY, Gao SS, Wang WZ. The inhibitory effect of Tripterygium wilfordii red pigment on the secretion of IL-17
410 by peripheral blood mononuclear cells in patients with sympathetic ophthalmitis. *Chinese Journal of Ocular Fundus*
411 *Diseases*. 34:51-54(2018).
- 412 53. Li M, Li Y, Xiang L. Efficacy and safety of Tripterygium glycosides as an add-on treatment in adults with chronic
413 urticaria: a systematic review and meta-analysis. *Pharm Biol*. 61:324-336. doi:
414 10.1080/13880209.2023.2169468(2023).
- 415 54. Xie D, Li K, Ma T, Jiang H, Wang F, Huang M, et al. Therapeutic Effect and Safety of Tripterygium Glycosides
416 Combined With Western Medicine on Type 2 Diabetic Kidney Disease: A Meta-Analysis. *Clin Ther*. 44:246-
417 256.e10. doi: 10.1016/j.clinthera(2022).
- 418 55. Li WW, Liu XL, Wu H, et al. Efficacy and Safety of Tripterygium wilfordii Hook.F for IgA Nephropathy: A Meta-
419 analysis. *Chin J Evid-based Med*. 15:206-214(2015).
- 420 56. Zhang XM, Xiang SM. Analysis of randomized clinical trials of oral GTT tablets in the treatment of psoriasis
421 vulgaris. *Guide of China Medicine*. 27:392-393(2013).

- 422 57.Wang JQ, Li GC, Zhou XP, Ma Z. Tripterygium wilfordii extraction for treating rheumatoid arthritis: a meta-
423 analysis. *Modern Journal of Integrated Traditional Chinese and Western Medicine*. 23:1032-1036(2014).
- 424 58.Huang Q, Zeng QM, Zheng YH, Xiong JL. Meta Analysis of Tripterygium wilfordii Combined Glucocorticoid
425 therapy in NS Patients. *Journal of Liaoning University of TCM*. 17:145-149(2015).
- 426 59.Sun ZQ. Medical statistics.*Beijing: People's Health Publishing House*.623(2002).
- 427 60.Wang JY. Evidence based medicine and clinical practice.*Beijing: Science press*.118-121(2002).

428 **Fundings**

- 429 Foundation of Liaoning Province Education Administration(L202073). Foundation of Liaoning Province
430 Education Administration (L201723). Liaoning Province Famous Traditional Chinese Medicine Studio Construction
431 Project.

432 **Author contributions**

- 433 Conceptualization: Mingzhe Li, Tianshu Gao.
- 434 Data curation: Mingzhe Li, Bingchen Wei.
- 435 Formal analysis: Bingchen Wei, Chenghan Gao.
- 436 Funding acquisition: Mingzhe Li, Tianshu Gao.
- 437 Investigation: Mingzhe Li, Bingchen Wei, Chenghan Gao.
- 438 Methodology: Mingzhe Li, Tianshu Gao.
- 439 Writing-original draft: Mingzhe Li, Bingchen Wei.
- 440 Writing-review: Mingzhe Li, Bingchen Wei, Chenghan Gao, Tianshu Gao.






A**B****C**


Figure 5




A




B




C



D



E



F

Figure6




Figure2




Figure3




Figure4




Figure 1